Head-to-head · Cost-Efficiency Index
PlushCare vs Levity
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
PlushCare
Patients who want a real board-certified physician managing GLP-1s alongside general primary care, and are prepared to navigate insurance or a manufacturer cash-pay program rather than a single flat price.
Visit PlushCareLevity
Cost-first shoppers who want all-inclusive branded GLP-1 pens with named clinical leadership, for shoppers willing to pay premium cash prices.
Visit LevityThe verdict
PlushCare takes it, leading the Cost-Efficiency Index 65 to 64. PlushCare (a Transcarent, Inc. subsidiary) is a virtual primary-care platform whose board-certified MDs can prescribe brand-name GLP-1s (via insurance or Novo Nordisk's NovoCare cash-pay program) or compounded semaglutide/tirzepatide in a roughly 39-state footprint. Levity still earns a C — Cost-first shoppers who want all-inclusive branded GLP-1 pens with named clinical leadership, for shoppers willing to pay premium cash prices.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs PlushCare.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | PlushCare | Levity |
|---|---|---|
| Cost-Efficiency Index | 65/100 | 64/100 |
| Semaglutide / mo | $199/mo (0.25 mg dose, plus a separate fee, brand-name) | $1,199/mo (brand Ozempic) |
| Tirzepatide / mo | $399/mo (5 mg dose, plus a separate fee, compounded) | $1,299/mo (brand Mounjaro) |
| Semaglutide / yr (modeled) | $2,388 | $14,388 |
| Tirzepatide / yr (modeled) | $4,788 | $15,588 |
| Coverage | All 50 states | 36 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Yes |
| Rank here | #166 | #172 |
PlushCare
65/100Where the value is
- Board-certified physicians (not NP-only) available in all 50 states for general virtual primary care
- Publishes an unusually granular compounded-tirzepatide dose ladder ($399/$599/$749 by vial count) instead of a vague single 'starting at' figure
- Brand Wegovy via NovoCare's manufacturer program can beat most compounded prices ($199-399/mo) when the promotion is genuinely still active
The tradeoffs
- Compounded tirzepatide and semaglutide are each only available in about 39 states plus DC, narrower than PlushCare's general 50-state telehealth business
- A $19.99/mo membership and, for uninsured patients, a $129 visit fee sit on top of every medication price and are easy to miss from the headline drug price alone
Levity
64/100Where the value is
- FDA-approved branded medications only (Ozempic, Mounjaro, Wegovy), with named clinical leadership (a licensed PharmD and a board-certified MD, both with license/NPI numbers shown)
- All-inclusive pricing covers consultation, prescription, medication and shipping in one recurring charge
- LegitScript-certified with a visible seal number
The tradeoffs
- Premium pricing: $1,199-$1,599/mo standing, among the most expensive options in the category
- Not a 50-state service — California and 14 other states are not on the published list
Regulatory note: the FDA issued a warning letter to Levity Inc. dba Levity in February 2026. We still list and link to Levity; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.